New DLBCL Regimen Has Extended Survival in Trial
Adults with relapsed or refractory lymphoma may have a new treatment option that could improve overall survival outcomes.
Updated on Oct. 10, 2026 in Cancer
Live Poll
Should medical researchers prioritize testing new combination drug therapies for difficult-to-treat cancer patients?
The POLARGO trial found that adding the drug polatuzumab vedotin to a standard chemotherapy regimen extended median overall survival to 19.5 months for transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approach significantly outperformed the standard chemotherapy alone, offering a potential new pathway for those with limited treatment options.
Why it matters
Patients who are ineligible for stem cell transplants often face a poor prognosis when their lymphoma relapses or stops responding to initial therapy. This new regimen addresses an urgent need for more effective treatments for this specific, difficult-to-treat population.
In a randomized trial of 255 adults, the Pola-R-GemOx regimen achieved a median overall survival of 19.5 months compared to 12.5 months for the R-GemOx control group. The complete response rate was 40.3% in the treatment group, nearly double the 19% rate seen in the control arm.
The players
European Hematology Association
A professional organization that supports hematology research and clinical education through annual international congresses.
Journal of Clinical Oncology
A peer-reviewed medical publication that reports on major oncology research and evidence-based cancer treatments.
The details
The trial assigned participants to receive either the experimental regimen or standard chemotherapy every 21 days for up to 8 cycles. The addition of polatuzumab vedotin to the R-GemOx chemotherapy backbone is designed to target specific proteins on B-cells to stop cancer cell growth. However, the treatment carried significant risks, with 57% of patients experiencing peripheral neuropathy and 12% experiencing fatal adverse events.
Timeline
The POLARGO trial findings were presented at the 2025 European Hematology Association congress.
The full results were published in 2026 in the Journal of Clinical Oncology.
Health Landscape
The POLARGO trial results provide a new benchmark for addressing relapsed or refractory DLBCL in patients ineligible for aggressive transplantation. This development represents a significant departure from standard chemotherapy-only approaches that have historically defined the treatment arc for this disease.
Patients and families navigating lymphoma treatment should discuss these findings with their hematologist to understand if such therapies are appropriate for their specific disease profile. It is essential to weigh the potential for increased survival against the significant risks of adverse events like peripheral neuropathy.
The takeaway
The addition of polatuzumab vedotin to standard chemotherapy appears to offer a survival advantage for patients who cannot undergo stem cell transplants. Individuals currently in treatment should track any symptoms of nerve damage, such as tingling or numbness, and report them to their care team immediately.
Further reading
For more information on current treatment standards and research developments, visit our Cancer section.
Source note: This article includes information reported by Ajmc.
Live Poll
Should medical researchers prioritize testing new combination drug therapies for difficult-to-treat cancer patients?
